ReviewHealthcare (Basel, Switzerland)2026
Artificial Intelligence for Early Detection and Prediction of Chronic Obstructive Pulmonary Disease Exacerbations.
Review in Healthcare (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExacerbations of chronic obstructive pulmonary disease (COPD) are a leading cause of morbidity, mortality, and healthcare burden worldwide. Early detection and timely intervention remain important challenges in COPD management, given the unpredictable nature of acute deterioration and limitations of traditional spirometry-based risk assessment.
methodsThis narrative review synthesizes artificial intelligence (AI)-driven approaches for predicting and detecting chronic obstructive pulmonary disease (COPD) exacerbations across electronic health records, wearable sensors, imaging, environmental data, and patient-reported outcomes, emphasizing novel discoveries and emerging relationships rather than predictive performance.
resultsThree major discoveries have been made. First, measurable physiological and behavioral deterioration may precede symptom recognition by approximately 7-14 days, thereby establishing a potential intervention window for anticipatory care. Second, machine learning (ML) models integrating pollutant exposure, medication adherence, and clinical characteristics have identified phenotypes with differential environmental sensitivity, including unexpected exposure-adherence interactions. Third, deep neural network analysis of full spirometry curves has revealed structural phenotypes beyond traditional Forced Expiratory Volume (FEV
conclusionsAI has uncovered hidden patterns in the progression of COPD, supporting a shift from reactive to anticipatory management. Translation to routine care requires prospective validation, improved interpretability, workflow integration, and generalizability and equity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.